生物活性

• 描述L-Thyroxine sodium (Levothyroxine sodium) is a synthetic hormone for the research of hypothyroidism^[3]. The topic of pharmacological interference on L-T4 (L-thyroxine) therapy addresses the patient with primary hypothyroidism, in whom periodic measurement of serum thyrotropin (TSH) is the biochemical target^[4]. Compared with L-T4 alone, replacement therapy with the combination of L-T4+L-T3 (L-triiodothyronine) shows favourable changes in serum lipid profile, but higher activation of bone resorption^[5]. Standard L-thyroxine supplementation in HT (Hashimoto's thyroiditis) patients exerted significant immunoregulatory effects, associated with quantitative and phenotypic changes of peripheral blood DC (dendritic cells) subpopulations^[6]. The thyroid hormone affects ventricular inhomogenicity, and that L-thyroxine replacement therapy may reduce malignant ventricular arrhythmia and sudden cardiac death in primary hypothyroidism^[7].
• 临床研究

• NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
  NCT03693612	Neoplasms	Phase 1 Phase 2	Recruiting	June 16, 2022	United States, Massachusetts ... more >> GSK Investigational Site Not yet recruiting Boston, Massachusetts, United States, 02215 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Centre    877-379-3718    GSKClinicalSupportHD@gsk.com    United States, New York GSK Investigational Site Not yet recruiting New York, New York, United States, 10016- Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Centre    877-379-3718    GSKClinicalSupportHD@gsk.com    GSK Investigational Site Not yet recruiting New York, New York, United States, 10032 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Centre    877-379-3718    GSKClinicalSupportHD@gsk.com    United States, Oklahoma GSK Investigational Site Not yet recruiting Oklahoma City, Oklahoma, United States, 73104 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Centre    877-379-3718    GSKClinicalSupportHD@gsk.com    United States, Pennsylvania GSK Investigational Site Not yet recruiting Pittsburgh, Pennsylvania, United States, 15232 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Centre    877-379-3718    GSKClinicalSupportHD@gsk.com    United States, Texas GSK Investigational Site Recruiting San Antonio, Texas, United States, 78240 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Centre    877-379-3718    GSKClinicalSupportHD@gsk.com    Principal Investigator: Anthony Tolcher          Australia, New South Wales GSK Investigational Site Not yet recruiting Darlinghurst, New South Wales, Australia, 2010 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Centre    877-379-3718    GSKClinicalSupportHD@gsk.com    Australia, Victoria GSK Investigational Site Not yet recruiting Melbourne, Victoria, Australia, 3000 Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Centre    877-379-3718    GSKClinicalSupportHD@gsk.com    Canada, Ontario GSK Investigational Site Not yet recruiting Ottawa, Ontario, Canada, K1H 8L Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Centre    877-379-3718    GSKClinicalSupportHD@gsk.com    GSK Investigational Site Not yet recruiting Toronto, Ontario, Canada, M5G 2M Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com    Contact: EU GSK Clinical Trials Call Centre    877-379-3718    GSKClinicalSupportHD@gsk.com Collapse <<
  NCT00945282	Infection, Human Immunodeficie... more >>ncy Virus Collapse <<	Phase 2	Completed	-	Argentina ... more >> GSK Investigational Site Buenos Aires, Argentina, B1602DBG Collapse <<
  NCT02705807	Cardiovascular Disease	Phase 4	Completed	-	Japan ... more >> GSK Investigational Site Okayama, Japan, 701-1192 Collapse <<

• 更多
• 参考文献

• [1] Schneider R, Reiners C. The effect of levothyroxine therapy on bone mineral density: a systematic review of the literature. Exp Clin Endocrinol Diabetes. 2003 Dec;111(8):455-70.

  [2] Nilsson SF, Peterson PA. Studies on thyroid hormone-binding proteins. I. The subunit structure of human thyroxine-binding globulin and its interaction with ligands. J Biol Chem. 1975 Nov 10;250(21):8543-53.

  [3] Arici M, Oztas E, Yanar F, Aksakal N, Ozcinar B, Ozhan G. Association between genetic polymorphism and levothyroxine bioavailability in hypothyroid patients. Endocr J. 2018 Mar 28;65(3):317-323

  [4] Benvenga S. L-T4 Therapy in the Presence of Pharmacological Interferents. Front Endocrinol (Lausanne). 2020 Dec 22;11:607446

  [5] Fadeyev VV, Morgunova TB, Melnichenko GA, Dedov II. Combined therapy with L-thyroxine and L-triiodothyronine compared to L-thyroxine alone in the treatment of primary hypothyroidism. Hormones (Athens). 2010 Jul-Sep;9(3):245-52

  [6] Stasiolek M, Dedecjus M, Adamczewski Z, Sliwka PW, Brzezinski J, Lewinski A. Effect of L-thyroxine treatment on peripheral blood dendritic cell subpopulations in patients with Hashimoto's thyroiditis. Folia Histochem Cytobiol. 2014;52(2):138-43

  [7] Kweon KH, Park BH, Cho CG. The effects of L-thyroxine treatment on QT dispersion in primary hypothyroidism. J Korean Med Sci. 2007 Feb;22(1):114-6

• 更多

• Collapse